‘Catch-22’ scenario good news for some cancer patients

Traits that allow cancer cells to escape the body’s natural defence system and develop into tumours are actually a good indicator to a patient’s survival prognosis, according to University of Queensland researchers.

UQ Diamantina Institute researcher Dr Janin Chandra described the discovery as a “catch-22 situation” and good news for patients with either cervical or head and neck cancer who have immune inhibitory traits present in their tumours.

“Our natural defence system is programmed to pick up abnormal cancerous cells and destroy them before they can grow into a tumour mass and spread through our bodies,” Dr Chandra said.

“However, the tumour can grow by developing cunning strategies to either escape our natural defence system, or to actively block it.

“We call these strategies immune inhibition, and until recently we thought this trait was a bad thing.

“Our recent research has shown that tumours of patients with either cervical cancer or head and neck cancer which had many immune inhibition traits, had the best five-year survival prognosis compared to patients with tumours without the traits.”

The data also showed that tumours with immune inhibition traits also had high levels of defence system activity, which fight against cancer.

Dr Chandra said researchers now had a better understanding that having immune inhibition traits in the tumour was actually not bad, and in fact was a sign of immune activation.

People who lack this immune activity inside the tumour, regardless if ‘good’ or ‘bad’ immune activity, have a worse prognosis.

She said this knowledge had important implications in designing future therapies for cancer.

“On average only 20 percent of patients respond to new immune-targeted drugs, so we are organising a clinical research study to develop predictors of response to these drugs,” Dr Chandra said.

“You need to give patients that aren’t responding to treatment an alternative, so our research is geared to identify new targets that could be used for patients who don’t have any natural defence cells in their tumours.”

Source: The University of Queensland